Abu-Raddad, Laith J.; Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Yassine, Hadi M.; Al-Khatib, Hebah A. et al. (2022): Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. In: The New England journal of medicine. DOI: 10.1056/NEJMoa2200797.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 2022; 386(16):1532–46. doi: 10.1056/NEJMoa2119451.
Arbel, R., Sergienko, R., Friger, M. et al. (2022): Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. In: Nat Med. DOI: 10.1038/s41591-022-01832-0.
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2
Bar-On, Yinon M.; Goldberg, Yair; Mandel, Micha; Bodenheimer, Omri; Amir, Ofra; Freedman, Laurence et al. (2022): Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. In: The New England journal of medicine 386 (18), S. 1712–1720. DOI: 10.1056/NEJMoa2201570.
Carbone L, Trinchillo MG, Di Girolamo R, Raffone A, Saccone G, Iorio GG et al. COVID-19 vaccine and pregnancy outcomes: A systematic review and meta-analysis. Int J Gynaecol Obstet 2022; 159(3):651–61. doi: 10.1002/ijgo.14336.
Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med 2021; 385(24):e83.
Chiew CJ, Premikha M, Chong CY, Wei WE, Ong B, Lye DC et al. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. The Lancet Infectious Diseases 2022. doi: 10.1016/S1473-3099(22)00573-4.
Citu IM, Citu C, Gorun F, Sas I, Bratosin F, Motoc A et al. The Risk of Spontaneous Abortion Does Not Increase Following First Trimester mRNA COVID-19 Vaccination. J Clin Med 2022; 11(6). doi: 10.3390/jcm11061698.
Cohen-Stavi, Chandra J.; Magen, Ori; Barda, Noam; Yaron, Shlomit; Peretz, Alon; Netzer, Doron et al. (2022): BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. In: The New England journal of medicine. DOI: 10.1056/NEJMoa2205011.
Danino D, Ashkenazi-Hoffnung L, Diaz A, Erps AD, Eliakim-Raz N, Avni YS et al. Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants. J Pediatr 2022. doi: 10.1016/j.jpeds.2022.09.059.
European Medicines Agency (EMA). Comirnaty: EPAR – Product information [online]. 2021. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf [02.11.2021].
Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK et al. Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. JAMA 2022. doi: 10.1001/jama.2022.4255.
Ferdinands, Jill M.; Rao, Suchitra; Dixon, Brian E.; Mitchell, Patrick K.; DeSilva, Malini B.; Irving, Stephanie A. et al. (2022): Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. In: MMWR. Morbidity and mortality weekly report 71 (7), S. 255–263. DOI: 10.15585/mmwr.mm7107e2.
Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA 2022; 327(22):2210–9. doi: 10.1001/jama.2022.7493.
Gazit, Sivan; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Pitzer, Virginia E.; Patalon, Tal (2022): Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. In: BMJ (Clinical research ed.) 377, e071113. DOI: 10.1136/bmj-2022-071113.
Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 2021; 385(24):e85.
Goldshtein I, Steinberg DM, Kuint J, Chodick G, Segal Y, Shapiro Ben David S et al. Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes. JAMA Pediatr 2022. doi: 10.1001/jamapediatrics.2022.0001.
Hameed I, Khan MO, Nusrat K, Mahmood S, Nash*t M, Malik S et al. Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis. Am J Infect Control 2022. doi: 10.1016/j.ajic.2022.08.014.
Hui L, Marzan MB, Rolnik DL, Potenza S, Pritchard N, Said JM et al. Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol 2022. doi: 10.1016/j.ajog.2022.10.040.
Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ 2021; 375:e067873.
Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022;7(6):600–612.
Khan FL, Nguyen JL, Singh TG, Puzniak LA, Wiemken TL, Schrecker JP et al. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. JAMA Netw Open 2022; 5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
Kislaya I, Machado A, Magalhães S, Rodrigues AP, Franco R, Leite PP et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Euro Surveill 2022; 27(37). doi: 10.2807/1560-7917.ES.2022.27.37.2200697.
Lauring, Adam S.; Tenforde, Mark W.; Chappell, James D.; Gaglani, Manjusha; Ginde, Adit A.; McNeal, Tresa et al. (2022): Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. In: BMJ (Clinical research ed.) 376, e069761. DOI: 10.1136/bmj-2021-069761.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 21:NEJMoa2108891. Epub ahead of print.Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603–15.
McConeghy KW, White EM, Blackman C, Santostefano CM, Lee Y, Rudolph JL et al. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(39):1235–8. doi: 10.15585/mmwr.mm7139a2.
Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun 2021; 12(1):6379.
Moro PL, Olson CK, Zhang B, Marquez P, Strid P. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System. Obstet Gynecol 2022; 140(3):421–7. doi: 10.1097/AOG.0000000000004889.
Natarajan K, Prasad N, Dascomb K, Irving SA, Yang D-H, Gaglani M et al. Effectiveness of hom*ologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen Johnson & Johnson) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep 2022; 71(13):495–502. doi: 10.15585/mmwr.mm7113e2.
Patalon T, Saciuk Y, Peretz A, Perez G, Lurie Y, Maor Y et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun 2022; 13(1):3203. doi: 10.1038/s41467-022-30884-6.
Paul-Ehrlich-Institut (PEI). Sicherheitsbericht. Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 31.03.2023 [online]. 2022. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-20-bis-31-03-22.pdf?__blob=publicationFile&v=5 [20.07.2022].
Paul-Ehrlich-Institut (PEI). Sicherheitsbericht. Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 31.11.2021 [online]. 2021. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-20-bis-30-11-21.pdf?__blob=publicationFile&v=7 [29.12.2021].
Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021; 27(12):2127–35.
Prasad S, Kalafat E, Blakeway H, Townsend R, O'Brien P, Morris E et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun 2022; 13(1):2414. doi: 10.1038/s41467-022-30052-w.
Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. mRNA Covid-19 vaccines in pregnancy: A systematic review. PLoS One 2022; 17(2):e0261350. doi: 10.1371/journal.pone.0261350.
Robert Koch-Institut. SARS-CoV-2: Virologische Basisdaten sowie Virusvarianten [online]. 2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Virologische_Basisdaten.html;jsessionid=18E1B4E5D3D3854381D33660E415607B.internet072?nn=13490888#doc14716546bodyText6 [28.10.2021].
Robert Koch-Institut. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19) vom 28.04.2022 2022 Apr 28.
Rottenstreich M, Sela HY, Rotem R, Kadish E, Wiener-Well Y, Grisaru-Granovsky S. Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. BJOG 2021; Sep 23. Online ahead of print
Rudan I, Millington T, Antal K, Grange Z, Fenton L, Sullivan C et al. BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12-17 years in Scotland. Lancet Reg Health Eur 2022; 23:100513. doi: 10.1016/j.lanepe.2022.100513.
Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Lancet 2022; 400(10346):97–103. doi: 10.1016/S0140-6736(22)01185-0.
Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A. (2021): Effectiveness of a third dose of BNT162b2 mRNA vaccine. J Infect Dis. 2022 Jan 5;225(1):30-33. DOI: 10.1093/infdis/jiab556.
Sacco, Chiara; Del Manso, Martina; Mateo-Urdiales, Alberto; Rota, Maria Cristina; Petrone, Daniele; Riccardo, Flavia et al. (2022): Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. In: Lancet (London, England) 400 (10346), S. 97–103. DOI: 10.1016/S0140-6736(22)01185-0.
SeyedAlinaghi S, MohsseniPour M, Saeidi S, Habibi P, Dashti M, Nazarian N et al. Complications of COVID-19 Vaccines during Pregnancy; a Systematic Review. Arch Acad Emerg Med 2022; 10(1):e76. doi: 10.22037/aaem.v10i1.1622.
Ständige Impfkommission am Robert Koch-Institut (RKI). Pressemitteilung der STIKO zur COVID-19-Auffrischimpfung bei Kindern und Jugendlichen im Alter von 12-17 Jahren (13.01.2022) [online].https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2022-01-13.html[14.01.2022]
Ständige Impfkommission am Robert Koch-Institut (RKI). Beschluss der STIKO zur 12. Aktualisierung der COVID-19-Impfempfehlung. Epidemiologisches Bulletin 2021;43:7–56. [online]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/43_21.pdf?__blob=publicationFile [02.11.2021].
Ständige Impfkommission am Robert Koch-Institut. Beschluss der STIKO zur 16. Aktualisierung der COVID-19-Impfempfehlung. Epidemiologisches Bulletin 2022;2:3-15 [online]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/01_22.pdf?__blob=publicationFile [29.12.2021].
Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. N Engl J Med 2022; 387(6):525–32. Doi: 10.1056/NEJMoa2203209.
Tartof SY, Frankland TB, Slezak JM, Puzniak L, Hong V, Xie F et al. Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. JAMA Netw Open 2022; 5(8):e2225162. doi: 10.1001/jamanetworkopen.2022.25162.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis 2022; 22(12):1663–5. doi: 10.1016/S1473-3099(22)00692-2.
Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK et al. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(12):459–65. doi: 10.15585/mmwr.mm7112e1.
Tenforde, Mark W.; Self, Wesley H.; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J.; Talbot, H. Keipp et al. (2022): Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. In: MMWR. Morbidity and mortality weekly report 71 (12), S. 459–465. DOI: 10.15585/mmwr.mm7112e1.
Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021 Sep 15:NEJMoa2110345. Online ahead of print.
Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y et al. Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 2022. doi: 10.1038/s41591-022-01818-y.
Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 2022. Verfügbar unter: https://pubmed.ncbi.nlm.nih.gov/35189624/.
Wainstock T, Yoles I, Sergienko R, Sheiner E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine 2021; 39(41):6037–40. doi: 10.1016/j.vaccine.2021.09.012.
Zou Y, Huang D, Jiang Q, Guo Y, Chen C. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Front Public Health 2022; 10:940956. doi: 10.3389/fpubh.2022.940956.
